SERVICE

GenoBro

Healthy embryos are the foundation of a successful pregnancy—together with GenoBro.

Through preimplantation genetic testing, we help identify chromosomally normal embryos, increasing the chances of pregnancy while easing parental concerns.

Preimplantation Genetic Testing (PGT) involves retrieving a few cells from embryos on day 3 or days 5–7 after in vitro fertilization (IVF). The DNA is amplified and analyzed using next-generation sequencing (NGS) to detect chromosomal abnormalities.
By selecting and transferring genetically normal embryos through PGT, the chances of achieving a successful pregnancy with IVF can be significantly improved.

Korea’s first preimplantation genetic screening test based on next-generation sequencing (NGS)

High accuracy

Minimal sample required

High sensitivity

Faster turnaround time

As of the first half of 2024, available at more than 52 hospitals nationwide

GT Testing Procedure: Sample Collection (Embryo Biopsy)

Day 3 embryo (Blastomere)
1~2 cells

Day 5–7 embryo (Trophectoderm)
5–10 cells

GenoBro
Dedicated PCR tube

Why is the GenoBro test important?

For an embryo created through IVF to successfully implant and sustain a pregnancy, not only its appearance but also its chromosomes must be normal.
Embryos with chromosomal abnormalities are more likely to fail implantation or cause recurrent miscarriage. In addition, as maternal age increases, the proportion of genetically normal embryos decreases.
To improve implantation rates and reduce the risk of miscarriage, it is essential to select chromosomally normal embryos for transfer through preimplantation testing.

Who should consider the GenoBro test?

  • Women of advanced maternal age (35 years or older)
  • Couples with a history of unexplained recurrent miscarriage
  • Those who have experienced repeated implantation failure
  • Couples in which one or both partners carry structural chromosomal abnormalities (e.g., translocations, inversions)
  • Those with a previous pregnancy affected by chromosomal abnormalities

What makes the GenoBro service unique

Fast 1 Day

  • Rapid turnaround time (TAT) with fresh embryo transfer
  • Samples received before 12:00 p.m.
  • Results available by 10:00 a.m. the following day

Safe Data

  • Established in Korea in 2012 (12 years of expertise)
  • Exclusively domestic sample transport and testing
  • Protection against overseas transfer of medical and DNA data

Easy Report

  • Reports provided in Korean
  • Integrated with LIMS (Laboratory Information Management System)
  • Convenient online upload/download of results
  • GenoBro consultation hotline available

What can the GenoBro test identify?

How is the GenoBro test performed?

Sample collection

Embryo biopsy (embryo cells)

Transport

Secure delivery by a certified courier service

Testing

Next-generation sequencing (NGS) analysis

Results

Detection of chromosomal abnormalities in embryos

Test Information

Test name GenoBro (Preimplantation Genetic Testing, PGT)
Method Next-generation sequencing (NGS) (NGS, Next Generation Sequencing)
Test items PGT-A: Screening for numerical chromosomal abnormalities in embryos PGT-SR: Screening for structural chromosomal abnormalities in embryos
Testing period Day 3 or Days 5–7 of in vitro embryo culture
Specimen information Day 3 embryo: blastomere cells (partial sample) Days 5–7 embryo: trophectoderm cells (partial sample)
Submission deadline By 12:00 p.m. (noon)
Turnaround time Next business day (if received before 12:00 p.m.) Two business days later (if received after 12:00 p.m.)

Test Limitations

  • Although preimplantation genetic testing (PGT) based on next-generation sequencing (NGS) offers significantly improved sensitivity and accuracy compared with traditional methods, the analysis is performed on a very small number of cells (1–10). As a result, testing may occasionally be inconclusive, and there remains a rare possibility of false-positive or false-negative results.
  • In addition, embryo mosaicism cannot be fully excluded. Therefore, when pregnancy is achieved following PGT, confirmatory diagnostic testing (such as amniocentesis or chorionic villus sampling) is recommended to verify whether the fetus has chromosomal abnormalities.
LIMS Access Precision GenoMom GenoBro ora™

Privacy Policy

The company informs customers through the Privacy Policy about how the personal information provided is used and what measures are taken to protect personal information.

Purpose of Collecting and Using Personal Information

- Identifying individuals, verifying real names, confirming intent to sign up, and ensuring age-restricted service usage based on service use.
- Fulfilling contracts related to service provision, such as billing for services provided, delivering content, purchasing and processing payments, and dispatching items or billing statements.
- Delivering notices, ensuring communication for handling complaints, and ensuring accurate delivery information for item shipments.
- Providing information on new services and offering personalized services.
- Facilitating smooth provision of high-quality services.

Personal Information Collected

- Name, company name, email, address, contact number, mobile phone number, inquiry details, and other optional items.

Retention and Use Period of Personal Information

- As a general rule, personal information is destroyed immediately once the purpose for its collection or provision has been fulfilled.
- However, for the purpose of ensuring smooth service consultations, the content of the consultation may be retained for 3 months after completion. In cases where other laws, such as the Act on the Consumer Protection in Electronic Commerce, require preservation, the information may be retained for a specified period.

Procedure and Method for Destroying Personal Information

The company, as a general rule, destroys personal information without delay after the purpose of collection and use has been fulfilled. Information entered for membership or other purposes is transferred to a separate database (or, in the case of paper records, to a separate file) and stored for a certain period according to internal policies and relevant laws before being destroyed. Personal information transferred to a separate database is not used for any other purpose unless required by law. Personal information stored in electronic file formats is deleted using technical methods that prevent the recovery of the records.

Refusal of Unauthorized E-mail Collection

GENOMECARE prohibits unauthorized email collection.

The collection of email addresses posted on this website using email collection programs or other technical devices is prohibited, and violators may be punished under the Act on Promotion of Information and Communications Network Utilization and Information Protection.